AstraZeneca announces baxdrostat meets the primary endpoint in Bax24 phase III trial in patients with resistant hypertension: Cambridge, UK Wednesday, October 8, 2025, 12:00 Hrs [ ...
Tohoku University researchers dispel the “plasma effect” myth in spark plasma sintering, showing that both SPS and hot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback